Cogent Biosciences (COGT) Competitors

Axsome Therapeutics (NASDAQ:AXSM) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Does the media favor AXSM or COGT?

In the previous week, Axsome Therapeutics and Axsome Therapeutics both had 15 articles in the media. Axsome Therapeutics' average media sentiment score of 0.56 beat Cogent Biosciences' score of 0.09 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Cogent Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has higher earnings & valuation, AXSM or COGT?

Cogent Biosciences has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$385.69M	14.13	-$287.22M	-$5.07	-21.54
Cogent Biosciences	N/A	N/A	-$255.86M	-$1.78	-6.68

Do analysts rate AXSM or COGT?

Axsome Therapeutics presently has a consensus price target of $178.00, suggesting a potential upside of 62.99%. Cogent Biosciences has a consensus price target of $18.70, suggesting a potential upside of 57.28%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Axsome Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	3.07
Cogent Biosciences	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82

Do insiders & institutionals hold more shares of AXSM or COGT?

81.5% of Axsome Therapeutics shares are owned by institutional investors. 22.3% of Axsome Therapeutics shares are owned by insiders. Comparatively, 7.3% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is AXSM or COGT more profitable?

Cogent Biosciences has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -49.88%. Cogent Biosciences' return on equity of -223.82% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-49.88%	-283.22%	-33.06%
Cogent Biosciences	N/A	-223.82%	-89.44%

Which has more risk & volatility, AXSM or COGT?

Axsome Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500.

Summary

Axsome Therapeutics beats Cogent Biosciences on 9 of the 14 factors compared between the two stocks.